This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1999 Apr 29;340(17):1330-40.

doi: 10.1056/NEJM199904293401706.

Chronic myeloid leukemia

Affiliations

PMID: 10219069
DOI: 10.1056/NEJM199904293401706

Review

Chronic myeloid leukemia

C L Sawyers. N Engl J Med. 1999.

. 1999 Apr 29;340(17):1330-40.

doi: 10.1056/NEJM199904293401706.

Author

Affiliation

¹ Department of Medicine and Molecular Biology Institute, University of California at Los Angeles, 90095-1678, USA. csawyers@med1.medsch.ucla.edu

PMID: 10219069
DOI: 10.1056/NEJM199904293401706

No abstract available

PubMed Disclaimer

Comment in

Chronic myeloid leukemia.
Nash I. Nash I. N Engl J Med. 1999 Sep 2;341(10):765. doi: 10.1056/NEJM199909023411016. N Engl J Med. 1999. PMID: 10475801 No abstract available.

Similar articles

[Chronic myeloid leukemia: progress and prospects].
Baccarani M, Russo D, Fanin R. Baccarani M, et al. Haematologica. 1991 Jun;76 Suppl 3:40-5. Haematologica. 1991. PMID: 1752539 Review. Italian. No abstract available.
[Chronic myeloid leukemia. New prospects for marrow autotransplantation].
Carella AM, Carlier P, Nati S, Congiu A, Pierluigi D, Raffo MR. Carella AM, et al. Haematologica. 1991 Jun;76 Suppl 3:337-51. Haematologica. 1991. PMID: 1684348 Review. Italian. No abstract available.
Current controversies on the role of interferon-alpha for therapy of chronic myeloid leukemia.
Heimpel H, Allan NC, Baccarani M, Guilhot F, Hehlmann R, Horowitz M, Kluin-Nelemans J, Schaefer U, Storb R, Thaler J. Heimpel H, et al. Bone Marrow Transplant. 1996 May;17 Suppl 3:S39. Bone Marrow Transplant. 1996. PMID: 8769699 No abstract available.
Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy.
Martinelli G, Testoni N, Amabile M, Bonifazi F, De Vivo A, Farabegoli P, Terragna C, Montefusco V, Ottaviani E, Saglio G, Russo D, Baccarani M, Rosti G, Tura S. Martinelli G, et al. Bone Marrow Transplant. 2000 Apr;25(7):729-36. doi: 10.1038/sj.bmt.1702207. Bone Marrow Transplant. 2000. PMID: 10745258
Chronic myeloid leukemia--advances in biology and new approaches to treatment.
Goldman JM, Melo JV. Goldman JM, et al. N Engl J Med. 2003 Oct 9;349(15):1451-64. doi: 10.1056/NEJMra020777. N Engl J Med. 2003. PMID: 14534339 Review. No abstract available.

See all similar articles

Cited by

Aberrant microRNA expression and its implications in the pathogenesis of leukemias.
Babashah S, Sadeghizadeh M, Tavirani MR, Farivar S, Soleimani M. Babashah S, et al. Cell Oncol (Dordr). 2012 Oct;35(5):317-34. doi: 10.1007/s13402-012-0095-3. Epub 2012 Sep 7. Cell Oncol (Dordr). 2012. PMID: 22956261 Review.
The Hippo pathway kinase Lats2 prevents DNA damage-induced apoptosis through inhibition of the tyrosine kinase c-Abl.
Reuven N, Adler J, Meltser V, Shaul Y. Reuven N, et al. Cell Death Differ. 2013 Oct;20(10):1330-40. doi: 10.1038/cdd.2013.83. Epub 2013 Jul 12. Cell Death Differ. 2013. PMID: 23852372 Free PMC article.
Kinetics of BCR-ABL Transcripts in Imatinib Mesylate treated Chronic Phase CML (CPCML), A Predictor of Response and Progression Free Survival.
Mahmoud HK, El Nahas Y, Abdel Moaty M, Abdel Fattah R, El Emary M, El Metnawy W. Mahmoud HK, et al. Int J Biomed Sci. 2009 Sep;5(3):223-8. Int J Biomed Sci. 2009. PMID: 23675141 Free PMC article.
Influence of major BCR-ABL1 transcript subtype on outcome in patients with chronic myeloid leukemia in chronic phase treated frontline with nilotinib.
Genthon A, Nicolini FE, Huguet F, Colin-Gil C, Berger M, Saugues S, Janel A, Hayette S, Cohny-Makhoul P, Cadoux N, Cayuela JM, Campos L, Guyotat D, Flandrin-Gresta P. Genthon A, et al. Oncotarget. 2020 Jun 30;11(26):2560-2570. doi: 10.18632/oncotarget.27652. eCollection 2020 Jun 30. Oncotarget. 2020. PMID: 32655840 Free PMC article.
Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study.
Wang X, Roy A, Hochhaus A, Kantarjian HM, Chen TT, Shah NP. Wang X, et al. Clin Pharmacol. 2013 Jun 10;5:85-97. doi: 10.2147/CPAA.S42796. Print 2013. Clin Pharmacol. 2013. PMID: 23788844 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information